[1] |
蔡秀军, 张斌, 陈鸣宇, 等. 我国腹腔镜肝切除术近10年进展与发展趋势[J]. 中国实用外科杂志, 2022, 42(9): 961-964.
|
[2] |
蒋利, 吴泓. 腹腔镜肝切除术的现状与展望[J]. 中国普外基础与临床杂志, 2020, 27(6): 11-15.
|
[3] |
Yoshida H, Taniai N, Yoshioka M, et al. Current status of laparoscopic hepatectomy[J]. J Nippon Med Sch, 2019, 86(4): 201-206.
|
[4] |
Abu Hilal M, Aldrighetti L, Dagher I, et al. The southampton consensus guidelines for laparoscopic liver surgery: from indication to implementation[J]. Ann Surg, 2018, 268(1): 11-18.
|
[5] |
Zhu AC, Agarwala A, Bao X. Perioperative fluid management in the enhanced recovery after surgery (ERAS) pathway[J]. Clin Colon Rectal Surg, 2019, 32(2): 114-120.
|
[6] |
中华医学会外科学分会肝脏外科学组. 腹腔镜肝切除术专家共识和手术操作指南(2013版)[J]. 中华外科杂志, 2013, 51(4): 289-292.
|
[7] |
国家卫生健康委员会. 原发性肝癌诊疗指南(2022年版)[J/CD]. 中华普通外科学文献(电子版), 2022, 16(2): 81-96.
|
[8] |
孙林茂, 梁英健, 刘连新. 腹腔镜肝段切除术的难点与策略[J/CD]. 中华普外科手术学杂志(电子版), 2019, 13(3): 232-234.
|
[9] |
于霜霜, 赵晓春. 围术期目标导向液体治疗策略与进展[J]. 医学综述, 2018, 24(21): 4286-4291.
|
[10] |
Kendrick JB, Kaye AD, Tong Y, et al. Goal-directed fluid therapy in the perioperative setting[J]. J Anaesthesiol Clin Pharmacol, 2019, 35(Suppl 1): S29-S34.
|
[11] |
Herner A, Haller B, Mayr U, et al. Accuracy and precision of ScvO2 measured with the CeVOX-device: A prospective study in patients with a wide variation of ScvO2-values[J]. PLoS One, 2018, 13(4): e0192073.
|
[12] |
陆志华, 王虹. 目标导向液体治疗对肝切除患者组织灌注及预后效果观察[J]. 国际医药卫生导报, 2020, 26(3): 432-435.
|
[13] |
Del Giudice M, Gangestad SW. Rethinking IL-6 and CRP: why they are more than inflammatory biomarkers, and why it matters[J]. Brain Behav Immun, 2018, 70: 61-75.
|
[14] |
Cerqueira C, Manfroi B, Fillatreau S. IL-10-producing regulatory B cells and plasmocytes: molecular mechanisms and disease relevance[J]. Semin Immunol, 2019, 44: 101323.
|